Similar articles for PMID: 28735423

Year	Number of Results
1947	1
1952	1
1978	1
1999	2
2001	1
2002	1
2010	2
2011	2
2012	4
2013	1
2014	10
2015	31
2016	41
2017	43
2018	34
2019	31
2020	20
2021	23
2022	9
2023	3
2024	0

1

The anticoagulant effect of heparin during radiofrequency ablation (RFA) in patients taking apixaban or rivaroxaban.

Brendel LC, Dobler F, Hessling G, Michel J, Braun SL, Steinsiek AL, Groha P, Eckl R, Deisenhofer I, Hyseni A, Roest M, Ott I, Steppich B. Brendel LC, et al. J Interv Card Electrophysiol. 2017 Sep;49(3):237-244. doi: 10.1007/s10840-017-0274-2. Epub 2017 Jul 22. J Interv Card Electrophysiol. 2017. PMID: 28735423

2

Effect of pre-procedural interrupted apixaban on heparin anticoagulation during catheter ablation for atrial fibrillation: a prospective observational study.

Bin Abdulhak AA, Kennedy KF, Gupta S, Giocondo M, Ramza B, Wimmer AP. Bin Abdulhak AA, et al. J Interv Card Electrophysiol. 2015 Nov;44(2):91-6. doi: 10.1007/s10840-015-0048-7. Epub 2015 Aug 21. J Interv Card Electrophysiol. 2015. PMID: 26292959

3

Effect of the FXa inhibitors Rivaroxaban and Apixaban on platelet activation in patients with atrial fibrillation.

Steppich B, Dobler F, Brendel LC, Hessling G, Braun SL, Steinsiek AL, Deisenhofer I, Hyseni A, Roest M, Ott I. Steppich B, et al. J Thromb Thrombolysis. 2017 May;43(4):490-497. doi: 10.1007/s11239-017-1495-z. J Thromb Thrombolysis. 2017. PMID: 28316004

4

Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.

Rillig A, Lin T, Plesman J, Heeger CH, Lemes C, Metzner A, Mathew S, Wissner E, Wohlmuth P, Ouyang F, Kuck KH, Tilz RR. Rillig A, et al. J Cardiovasc Electrophysiol. 2016 Feb;27(2):147-53. doi: 10.1111/jce.12856. Epub 2015 Nov 23. J Cardiovasc Electrophysiol. 2016. PMID: 26464027

5

Left atrial thrombus and dense spontaneous echocardiographic contrast in patients on continuous direct oral anticoagulant therapy undergoing catheter ablation of atrial fibrillation: Comparison of dabigatran, rivaroxaban, and apixaban.

Wu M, Gabriels J, Khan M, Shaban N, D'Amato S, Liu CF, Markowitz SM, Ip JE, Thomas G, Singh P, Lerman B, Patel A, Cheung JW. Wu M, et al. Heart Rhythm. 2018 Apr;15(4):496-502. doi: 10.1016/j.hrthm.2017.12.005. Heart Rhythm. 2018. PMID: 29605015

6

Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation.

Yoshimura A, Iriki Y, Ichiki H, Oketani N, Okui H, Maenosono R, Namino F, Miyata M, Ohishi M. Yoshimura A, et al. J Cardiol. 2017 Jan;69(1):228-235. doi: 10.1016/j.jjcc.2016.03.014. Epub 2016 Apr 27. J Cardiol. 2017. PMID: 27131792 Free article. Clinical Trial.

7

Incidence and predictors of silent cerebral thromboembolic lesions after catheter ablation for atrial fibrillation in patients treated with direct oral anticoagulants.

Doi A, Takagi M, Kakihara J, Hayashi Y, Tatsumi H, Fujimoto K, Sugioka K, Yoshiyama M. Doi A, et al. Heart Vessels. 2017 Oct;32(10):1227-1235. doi: 10.1007/s00380-017-0985-4. Epub 2017 May 2. Heart Vessels. 2017. PMID: 28466408

8

Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation.

Nagao T, Inden Y, Shimano M, Fujita M, Yanagisawa S, Kato H, Ishikawa S, Miyoshi A, Okumura S, Ohguchi S, Yamamoto T, Yoshida N, Hirai M, Murohara T. Nagao T, et al. Pacing Clin Electrophysiol. 2015 Feb;38(2):155-63. doi: 10.1111/pace.12553. Epub 2014 Dec 9. Pacing Clin Electrophysiol. 2015. PMID: 25487164

9

Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study.

Testa S, Legnani C, Tripodi A, Paoletti O, Pengo V, Abbate R, Bassi L, Carraro P, Cini M, Paniccia R, Poli D, Palareti G. Testa S, et al. J Thromb Haemost. 2016 Nov;14(11):2194-2201. doi: 10.1111/jth.13486. Epub 2016 Oct 15. J Thromb Haemost. 2016. PMID: 27566988 Free article.

10

Activated clotting time on the day of atrial fibrillation ablation for minimally interrupted and uninterrupted direct oral anticoagulation therapy: Sequential changes, differences among direct oral anticoagulants, and ablation safety outcomes.

Yamaji H, Murakami T, Hina K, Higashiya S, Kawamura H, Murakami M, Kamikawa S, Hirohata S, Kusachi S. Yamaji H, et al. J Cardiovasc Electrophysiol. 2019 Dec;30(12):2823-2833. doi: 10.1111/jce.14260. Epub 2019 Nov 12. J Cardiovasc Electrophysiol. 2019. PMID: 31701593 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

216 results

Results by year